Immuron Ltd — Regulatory Filings 2007

Apr 11, 2007

Company Announcement

Sale and Lease back of Premises

Thursday 12 April 2007

Anadis Ltd (ASX:ANX) has entered in to an unconditional contract for the sale and lease-back of its premises at 4 Capital Link Drive in Campbellfield, Melbourne. A sale price of \$1.2 million for the property was achieved.

This sale is part of the strategic review currently being undertaken at Anadis.

Anadis has a 5+5 year lease on the property and believes that this provides the flexibility and freedom which will enable Anadis to capitalise on the value of its products and research, rather than have value locked up in static assets.

The proceeds will be used to further the commercialisation of our Enterovirus 71 preventative, expand the "Ectoplasm" program, and hasten our continued expansion into the US focused on the development of high value therapies for large markets with unmet needs through international research and clinical efforts.

For further information, please contact:

Arie Nudel - Investor Relations Email: arie.n@anadis.com.au Tel: $+61393586388$

Roman Zwolenski – Executive Director Email: roman.z@anadis.com.au Tel: $+61$ 3 9358 6388

About Anadis Limited:

Anadis, a Melbourne based biopharmaceutical company is focused on Nutraceutical and Pharmaceutical research and development. Anadis is a specialist in the development of Dairy (bovine) colostrum derived products for therapeutic use in humans. Projects include:

Anadis' first commercialised product: Travelan is a natural product, which significantly decreases the risk of the medical condition known as Travellers Diarrhoea and the symptoms of gastrointestinal disorders. Travelan is a colostrum preparation, against the common strains of $\vec{E} \cdot \vec{col}$ the most common cause of Travellers.

Travelan which has received a "Green Light' for sales in North America, now has US and Canadian distributors appointed. Travelan distribution is currently being developed for other markets including: Singapore, India. Korea, United Arab Emirates, Thailand, Malaysia, South Africa and the UK and EU.

Travelan has recently been potentially identified for additional gastrointestinal indications including Irritable Bowel Syndrome IBS and Inflammatory Bowel Disorder IBD.

For more information please visit www.travelan.com

$EV-71$ - a preventative product containing a bioactive protein against Enterovirus 71, a virus that causes a debilitating polio-like illness as well as hand, foot and mouth disease. Young children are particularly vulnerable to infection with Enterovirus 71 with a significant number fatal cases. Anadis is now preparing colostrum antibodies for commercialisation in an anti-EV71 preventative, set to begin marketing in Taiwan during the northern hemisphere summer of 2007.

Ectoplasm Program - A project in conjunction with Australian emergency response agencies, including the Defence Science and Technology Organisation, developing a system for the containment and decontamination of hazardous materials, using a gel-like substance, combined with an active agent such as Anadis' anti-anthrax antibodies, for use by emergency service first responders at the scene of an incident.

A set of Bio-Defence and Respiratory Protection technologies, a project in conjunction with the Australian Department of Defence and US Bio-Defence Organisations, initially focused on short-term immediate protection from airborne bacteria such as Anthrax and Plague, future civilian applications include Hay Fever and Asthma.

This project is expanding to examine the use of antibodies in providing respiratory protection against Influenza virus.

Bio-Shield 10 a range of "bio-shielding" technologies which protect delicate molecules, enzymes and proteins, initially targeted for use in the pro-biotic market.

Development into an Immune Stimulating Infant Formula is underway, initially destined for the Asian market.

Pyloran, which has been clinically proven to reduce levels of H.pylori bacteria in the stomach and reduce the symptoms of H.pylori associated gastritis - Anadis is also in early development of a H.pylori vaccine.

Anadis - Delivering On The Promise Of Biotechnology

Visit our websites: www.anadis.com.au and www.travelan.com